In vitro effect of genistein on DNA damage in leukocytes from mucopolysaccharidosis IVA patients

Molecular Genetics and Metabolism

Volumn 111, Issue 2, 2014, Pages 205-208

  Negretto, G W ^a,b   Deon, M ^b   Burin, M ^b   Biancini, G B ^b   Ribas, G ^b   Garcia, S C ^a   Goethel, G ^a   Fracasso, R ^a   Giugliani, L ^b   Giugliani, R ^b   Vargas, C R ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Comet assay; DNA damage; Genistein; Genotoxicity; Mucopolysaccharidosis IVA

Indexed keywords

GENISTEIN;

ARTICLE; COMET ASSAY; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LEUKOCYTE; MORQUIO SYNDROME TYPE A; MUCOPOLYSACCHARIDOSIS; PRIORITY JOURNAL;

COMET ASSAY; DNA DAMAGE; GENISTEIN; GENOTOXICITY; MUCOPOLYSACCHARIDOSIS IVA;

ADOLESCENT; ADULT; CELLS, CULTURED; CHILD; COMET ASSAY; DNA FRAGMENTATION; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENISTEIN; HUMANS; LEUKOCYTES, MONONUCLEAR; MALE; MUCOPOLYSACCHARIDOSIS IV;

EID: 84893661389     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2013.11.011     Document Type: Article

References (33)

1. Montaño A.M., Tomatsu S., Gottesman G.S., Smith M., Orii T. International Morquio A Registry: clinical manifestation and natural course of Morquio A disease. J. Inherit. Metab. Dis. 2007, 30:165-174.
2. Dvorak-Ewell M., Wendt D., Hague C., Christianson T., Koppaka V., Crippen D., Kakkis E., Vellard M. Enzyme replacement in a human model of mucopolysaccharidosis IVA in vitro and its biodistribution in the cartilage of wild type mice. PLoS One 2010, 5(8):e12194.
3. Martell L., Lau K., Mei M., Burnett V., Decker C., Foehr E.D. Biomarker analysis of Morquio syndrome: identification of disease state and drug responsive markers. Orphanet J. Rare Dis. 2011, 16(6):84.
4. Tomatsu S., Montaño A.M., Oikawa H., Smith M., Barrera L., Chinen Y., Thacker M.M., Mackenzie W.G., Suzuki Y., Orii T. Mucopolysaccharidosis type IVA (Morquio A disease): clinical review and current treatment: a special review. Curr. Pharm. Biotechno. 2011, 12(6):931-945.
5. Piotrowska E., Jakobkiewicz-Banecka J., Tylki-Szymanska A., Liberek A., Maryniak A., Malinowska M., Czartoryska B., Puk E., et al. Genistein-rich soy isoflavone extract in substrate reduction therapy for Sanfilippo syndrome: an open-label, pilot study in 10 pediatric patients. Curr. Ther. Res. 2008, 69(2):166-179.
6. Tirone E., D'Alessandris C., Hascall V.C., Siracusa G., Salustri A. Hyaluronan synthesis by mouse cumulus cells is regulated by interactions between follicle-stimulating hormone (or epidermal growth factor) and a soluble oocyte factor (or transforming growth factor beta1). J. Biol. Chem. 1997, 272(8):4787-4794.
7. Akiyama T., Ishida J., Nakagawa S., Ogawara H., Watanabe S., Itoh N., Shibuya M., Fukami Y. Genistein, a specific inhibitor of tyrosine-specific protein kinase. J. Biol. Chem. 1987, 262(12):5592-5595.
8. Kim H., Peterson T.G., Barnes S. Mechanisms of action of the soy isoflavone genistein:emerging role for its effects via transforming growth factor beta signaling pathways. Am. J. Clin. Nutr. 1998, 68(Suppl.6):1418S-1425S.
9. Jakóbkiewicz-Banecka J., Piotrowska E., Narajczyk M., Barańska S., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis, which corrects storage in cells of patients suffering from mucopolysaccharidoses, acts by influencing an epidermal growth factor-dependent pathway. J. Biomed. Sci. 2009, 16:26.
10. Friso A., Tomanin R., Salvalaio M., Scarpa M. Genistein reduces glycosaminoglycan levels in a mouse model of mucopolysaccharidosis type II. Br. J. Pharmacol. 2010, 159(5):1082-1091.
11. Malinowska M., Wilkinson F.L., Bennett W., Langford-Smith K.J., O'leary H.A., Jakobkiewicz-Banecka J., Wynn R., Wraith J.E., Wegrzyn G., Bigger B.W. Genistein reduces lysosomal storage in peripheral tissues of mucopolysaccharide IIIB mice. Mol. Genet. Metab. 2009, 98(3):235-242.
12. Malinowska M., Wilkinson F.L., Langford-Smith K.J., Langford-Smith A., Brown J.R., et al. Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 2010, 5(12):e14192.
13. De Ruijter J., Valstar M.J., Narajczyk M., Wegrzyn G., Kulik W., Basc L.I., Basc T.W., Van Der Wal W.M., Wijburg F.A. Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann. Neurol. 2012, 71(1):110-120.
14. Delgadillo V., O'Callaghan M.M., Artuch R., Montero R., Pineda M. Genistein supplementation in patients affected by Sanfilippo disease. J. Inherit. Metab. Dis. 2011, 34(5):1039-1044.
15. Malinová V., Wegrzyn G., Narajczyk M. The use of elevated doses of genistein-rich soy extract in the gene expression-targeted isoflavone therapy for Sanfilippo disease patients. J. Inherit. Metab. Dis. 2012, 5:21-25.
16. Marucha J., Tylki-Szymanska A., Jakóbkiewicz-Banecka J., Piotrowska E., Kloska A., Czartoryska B., Wegrzyn G. Improvement in the range of joint motion in seven patients with mucopolysaccharidosis type II during experimental gene expression-targeted isoflavone therapy (GET IT). Am. J. Med. Genet. A 2011, 155:2257-2262.
17. Narajczyk M., Tylki-Szymańska A., Wegrzyn G. Changes in hair morphology as a biomarker in gene expression-targeted isoflavone therapy for Sanfilippo disease. Gene 2012, 504:292-295.
18. Piotrowska E., Jakobkiewicz-Banecka J., Maryniak A., Tylki-Szymanska A., Puk E., Liberek A., Wegrzyn A., Czartoryska B., Slominska-Wojewodzka M., Wegrzyn G. Two-year follow-up of Sanfilippo disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med. Sci. Monit. 2011, 17(4):CR196-CR202.
19. Bianco N.R., Chaplin L.J., Montano M.M. Differential induction of quinone reductase by phytoestrogens and protection against oestrogen-induced DNA damage. Biochem. J. 2005, 385:279-287.
20. Wu H.J., Chan W.H. Genistein protects methylglyoxal-induced oxidative DNA damage and cell injury in human mononuclear cells. Toxicol. In Vitro 2007, 21:335-342.
21. Kulling S.E., Metzler M. Induction of micronuclei, DNA strand breaks and HPRT mutations in cultured Chinese hamster V79 cells by the phytoestrogen coumoestrol. Food Chem. Toxicol. 1997, 35(6):605-613.
22. Di Virgilio A.L., Iwami K., Watjen W., Kahl R., Degen G.H. Genotoxicity of the isoflavones genistein, daidzein and equol in V79 cells. Toxicol. Lett. 2004, 151(1):151-162.
23. Kulling S.E., Rosenberg B., Jacobs E., Metzler M. The phytoestrogens coumoestrol and genistein induce structural chromosomal aberrations in cultured human peripheral blood lymphocytes. Arch. Toxicol. 1999, 73(1):50-54.
24. De Jong J.G.N., Wevers R.A., Liebrand-van Sambeek R. Measuring urinary glycosaminoglycans in the presence of protein: an improved screening procedure for mucopolysaccharidoses based on dimethylmethylene blue. Clin. Chem. 1992, 38:803-807.
25. Piotrowska E., Jakobkiewicz-Banecka J., Baranska S., Tylki-Szymańska A., Czartoryska B., Wegrzyn A., Wegrzyn G. Genistein-mediated inhibition of glycosaminoglycan synthesis as a basis for gene expression-targeted isoflavone therapy for mucopolysaccharidoses. Eur. J. Hum. Genet. 2006, 14(7):846-852.
26. Arfi A., Richard M., Gandolphe C., Scherman D. Storage correction in cells of patients suffering from mucopolysaccharidoses types IIIA and VII after treatment with genistein and other isoflavones. J. Inherit. Metab. Dis. 2010, 33:61-67.
27. Huang J., Nasr M., Kaimnd Y., Matthew H.R. Genistein inhibits protein histidine kinase. J. Biol. Chem. 1992, 267(22):15511-15515.
28. Tice R.R., Agurell D., Anderson D., Burlinson B., Hartmann A., Kobayashi H., Miyamae Y., Rojas E., Ryu J.C., Sasaki Y.F. Single cell gel/comet assay: guidelines for in vitro and in vivo genetic toxicology testing. Environ. Mol. Mutagen. 2000, 35:206-221.
29. Hartmann A., Agurell E., Beevers C., Brendler-Schwaab S., Burlinson B., Clay P., Collins A., Smith G., Speit G., Thybaud V., Tice R.R. Recommendations for conducting the in vivo alkaline comet assay. Mutagenesis 2003, 18:45-51.
30. Kim K.H., Dodsworth C., Paras A., Burton B.K. High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol. Genet. Metab. 2013, 109(4):382-385.
31. Miltyk W., Craciunescu C.N., Fischer L., Jeffcoat R.A., Koch M.A., Lopaczynski W., Mahoney C., Jeffcoat R.A., Crowell J., Paglieri J., Zeisel S.H. Lack of significant genotoxicity of purified soy isoflavones (genistein, daidzein, and glycitein) in 20 patients with prostate cancer. Am. J. Clin. Nutr. 2003, 77(4):875-882.
32. Kim Y.M., Yang S., Xu W., Li S., Yang X. Continuous in vitro exposure to low dose genistein induces genomic instability in breast epithelial cells. Cancer Genet. Cytogenet. 2008, 186(2):78-84.
33. Singh N., Mccoy M., Tice R., Schneider E. A simple technique for quantification of low levels of DNA damage in individuals cells. Exp. Cell Res. 1998, 175:184-191.